MedKoo Cat#: 461879 | Name: Bidisomide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bidisomide is a medication of the corticosteroid type with antiarrhythmic effects.

Chemical Structure

Bidisomide
Bidisomide
CAS#103810-45-3

Theoretical Analysis

MedKoo Cat#: 461879

Name: Bidisomide

CAS#: 103810-45-3

Chemical Formula: C22H34ClN3O2

Exact Mass: 407.2340

Molecular Weight: 407.98

Elemental Analysis: C, 64.77; H, 8.40; Cl, 8.69; N, 10.30; O, 7.84

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Bidisomide; Pulmicort; SC 40230; SC-40230; SC40230;
IUPAC/Chemical Name
2-(2-chlorophenyl)-4-(N-isopropylacetamido)-2-(2-(piperidin-1-yl)ethyl)butanamide
InChi Key
GTEPPJFJSNSNIH-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H34ClN3O2/c1-17(2)26(18(3)27)16-12-22(21(24)28,19-9-5-6-10-20(19)23)11-15-25-13-7-4-8-14-25/h5-6,9-10,17H,4,7-8,11-16H2,1-3H3,(H2,24,28)
SMILES Code
O=C(N)C(C1=CC=CC=C1Cl)(CCN(C(C)=O)C(C)C)CCN2CCCCC2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 407.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators. Circulation. 1997 Oct 21;96(8):2625-32. PubMed PMID: 9355903. 2: Pao LH, Zhou SY, Cook C, Kararli T, Kirchhoff C, Truelove J, Karim A, Fleisher D. Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-administration: relationship with region-dependent intestinal absorption. Pharm Res. 1998 Feb;15(2):221-7. PubMed PMID: 9523307. 3: Martin CL, Palomo MA, Mcmahon EG. Comparison of bidisomide, flecainide and dofetilide on action potential duration in isolated canine atria: effect of isoproterenol. J Pharmacol Exp Ther. 1996 Jul;278(1):154-62. PubMed PMID: 8764346. 4: Cook CS, Ames GB, Smith ME, Kowalski KG, Karim A. Absorption and disposition of a new antiarrhythmic agent bidisomide in man. Pharm Res. 1993 Nov;10(11):1675-82. PubMed PMID: 8290484. 5: Komori S, Sano S, Li BH, Matsumura K, Naitoh A, Mochizuki S, Ishihara T, Watanabe A, Umetani K, Ijiri H, et al. Effects of bidisomide (SC-40230), a new class I antiarrhythmic agent, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats; comparison with mexiletine and disopyramide. Heart Vessels. 1995;10(1):7-11. PubMed PMID: 7537263. 6: Homma N, Tsujimoto G, Hashimoto K. Electrophysiologic effects of an antiarrhythmic agent, bidisomide, on sodium current in isolated rat ventricular myocytes: comparison with mexiletine and disopyramide. Jpn J Pharmacol. 2001 May;86(1):23-31. PubMed PMID: 11430469. 7: Cook CS, Lonien M, Hribar J. Effect of diet and gavage on the dose- and dose-mode-dependent absorption and metabolism of bidisomide in rat. Xenobiotica. 2000 May;30(5):523-33. PubMed PMID: 10875685. 8: Lee KH, Xu GX, Schoenhard GL, Cook CS. Mechanisms of food effects of structurally related antiarrhythmic drugs, disopyramide and bidisomide in the rat. Pharm Res. 1997 Aug;14(8):1030-8. PubMed PMID: 9279885. 9: Cook CS, McDonald SJ, Karim A. Importance of pharmacokinetic and physicochemical data in the discovery and development of novel anti-arrhythmic drugs. Xenobiotica. 1993 Nov;23(11):1299-309. PubMed PMID: 8310713. 10: Vandenberghe Y, Masson M, Palate B, Roba J. Effect of folate supplementation on clinical chemistry and hematologic changes related to bidisomide administration in the rat. Drug Chem Toxicol. 1995 Nov;18(4):235-70. PubMed PMID: 8586020. 11: Cook CS, Zhang L, Osis J, Schoenhard GL, Karim A. Mechanism of compound- and species-specific food effects of structurally related antiarrhythmic drugs, disopyramide and bidisomide. Pharm Res. 1998 Mar;15(3):429-33. PubMed PMID: 9563073. 12: Cook CS, Ames GB, Hribar JD, Liu NW, Sweeney DL, Schoenhard GL, Karim A. Metabolism of a novel antiarrhythmic agent, bidisomide, in man: use of high resolution mass spectrometry to distinguish desisopropyl bidisomide from desacetyl bidisomide. Xenobiotica. 1995 Sep;25(9):981-91. PubMed PMID: 8553691. 13: Hackett AM, Gardiner P, Garthwaite SM. The effect of bidisomide (SC-40230), a new class Ia/Ib antiarrhythmic agent, on defibrillation energy requirements in dogs with healed myocardial infarctions. Pacing Clin Electrophysiol. 1993 Feb;16(2):317-26. PubMed PMID: 7680461. 14: Zhenjiu W, Awaji T, Hirasawa A, Motomura S, Hashimoto K. Effects of a new class I antiarrhythmic drug bidisomide on canine ventricular arrhythmia models. Mol Cell Biochem. 1993 Feb 17;119(1-2):159-69. PubMed PMID: 8455577. 15: Schmidt JJ, Frederick LG, Garthwaite SM. Rapid infusions of bidisomide or disopyramide in conscious dogs: effect of myocardial infarction on acute tolerability. J Cardiovasc Pharmacol. 1992 Aug;20(2):236-50. PubMed PMID: 1381015. 16: Page RL, Wharton JM, Wilkinson WE, Friedman IM, Claypool WD, Karim A, Kowalski KG, McDonald SJ, Gardiner P, Pritchett EL. Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics. Clin Pharmacol Ther. 1992 Apr;51(4):371-8. PubMed PMID: 1563207. 17: Rogister A, Vandenberghe Y, Roba J. Deoxyuridine suppression test on isolated rat bone marrow cells and the in vitro effect of bidisomide. Toxicol In Vitro. 1994 Apr;8(2):277-82. PubMed PMID: 20692917. 18: Skanchy DJ, Xie GH, Tait RJ, Luna E, Demarest C, Stobaugh JF. Application of sulfobutylether-beta-cyclodextrin with specific degrees of substitution for the enantioseparation of pharmaceutical mixtures by capillary electrophoresis. Electrophoresis. 1999 Sep;20(13):2638-49. PubMed PMID: 10532329. 19: Kowalski KG, Karim A. A semicompartmental modeling approach for pharmacodynamic data assessment. J Pharmacokinet Biopharm. 1995 Jun;23(3):307-22. PubMed PMID: 8834198. 20: Frederick LG, McDonald SJ, Garthwaite SM. Cardiovascular profile of a new anti-arrhythmic agent, SC-40230. Cardiovasc Res. 1989 Oct;23(10):897-903. PubMed PMID: 2620317.